REDWOOD CITY, CA – October 27, 2020 — Ashvattha Therapeutics, a clinical-stage biotech company focused on novel hydroxyl dendrimer therapeutics (HDTs) to treat unmet medical needs in oncology, ocular, and inflammatory diseases, today announced results from a preclinical study demonstrating the successful localization of HDs to target sites of inflammation in arthritic tissues at the ACR Convergence 2020, held virtually November 5-9, 2020.
Details for the virtual poster presentation are as follows:
- Presentation Title: Systemic Administration of Novel Hydroxyl Dendrimers to Target Inflammation in Arthritic Tissues
- Presentation Date & Time: Saturday, November 7, 2020, 9:00 AM – 11:00 AM EDT
- Abstract Number: 0738
- Presenters: Jeffrey Cleland, et al.
- Session: RA – Animal Models Poster
- Session Type: Poster Session B
In arthritis and other autoimmune disorders, chronic inflammation is mediated primarily by pro-inflammatory reactive macrophages. Systemic administration of anti-inflammatory agents does not selectively target the affected tissue, or the reactive macrophages and often has significant side effects. HDs have been observed to selectively target reactive macrophages and have been well tolerated in humans. HDTs may provide a superior method for treating localized inflammation, from systemic administration.
In a preclinical study, systemically administered HDs localized to sites of inflammation in arthritic tissues. When alendronate, which binds bone, was conjugated to the HD, the HD was targeted to the bone with less uptake in reactive macrophages away from the bone. These bone targeted HDs (btHDs) demonstrate the ability to tune HDs for targeting specific tissues and treat inflammation and/or bone metabolism. Efficacy studies are planned with btHD therapeutics to evaluate modulators of bone resorption and inflammation.
“We are excited to present this compelling preclinical data at ACR Convergence, which illustrate the selective targeting to inflammatory cells and tuning of HDs to target specific tissues,” said Jeffrey Cleland, Ph.D., Chairman, CEO & President at Ashvattha Therapeutics. “This data represents further expansion of our HD platform, and we look forward to utilizing these findings to develop tissue targeted therapeutics for oncology and autoimmune applications.”
For more information, abstracts are available online at https://acrabstracts.org.
About Ashvattha Therapeutics
Ashvattha Therapeutics, a clinical stage biopharmaceutical company, is developing novel therapeutics that target and alter specific cells in areas of diseased tissues. The Company’s targeted platform technology, hydroxyl dendrimers (HD), is exclusively licensed from Johns Hopkins University. HDs chemically conjugated to disease modifying drugs create novel proprietary HD therapeutics (HDTs). Ashvattha has initiated multiple programs with HDTs focused on oncology, age-related macular degeneration, or AMD, hyperinflammation in diseases such as COVID-19 and neuroinflammatory diseases such as ALS and Alzheimer’s disease. For more information, visit: www.avttx.com